Sangamo showcases Fabry progress at WORLDSymposium™

Uncategorized

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 4, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results.